These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 25432503)
1. What is the next generation therapeutic strategy for castration-resistant prostate cancer. Wen SM; Quan CY; Jiang N; Shang ZQ; Niu YJ Asian J Androl; 2015; 17(2):223-4. PubMed ID: 25432503 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Asangani IA; Dommeti VL; Wang X; Malik R; Cieslik M; Yang R; Escara-Wilke J; Wilder-Romans K; Dhanireddy S; Engelke C; Iyer MK; Jing X; Wu YM; Cao X; Qin ZS; Wang S; Feng FY; Chinnaiyan AM Nature; 2014 Jun; 510(7504):278-82. PubMed ID: 24759320 [TBL] [Abstract][Full Text] [Related]
3. Prostate cancer: novel targeting of androgen signalling in CRPC. Phillips R Nat Rev Urol; 2014 Jun; 11(6):303. PubMed ID: 24818852 [No Abstract] [Full Text] [Related]
4. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
6. BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer. Lochrin SE; Price DK; Figg WD Cancer Biol Ther; 2014; 15(12):1583-5. PubMed ID: 25535892 [TBL] [Abstract][Full Text] [Related]
7. BETting on a new prostate cancer treatment. Asangani IA; Chinnaiyan AM Cell Cycle; 2014; 13(13):2015-6. PubMed ID: 24905827 [No Abstract] [Full Text] [Related]
8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N; Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502 [TBL] [Abstract][Full Text] [Related]
9. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Blee AM; Liu S; Wang L; Huang H Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196 [TBL] [Abstract][Full Text] [Related]
11. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer. Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963 [TBL] [Abstract][Full Text] [Related]
12. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer. Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197 [TBL] [Abstract][Full Text] [Related]
13. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323 [TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of drug resistance in endocrinotherapy for castration-resistant prostate cancer]. Bo B; Guo JB; Liu LR; Wei Q Zhonghua Nan Ke Xue; 2021 Feb; 27(2):167-171. PubMed ID: 34914335 [TBL] [Abstract][Full Text] [Related]
15. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer. Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036 [TBL] [Abstract][Full Text] [Related]
16. Targeting the androgen receptor signaling pathway in advanced prostate cancer. Chung C; Abboud K Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118 [TBL] [Abstract][Full Text] [Related]
18. Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo. Liu J; Zhang R; Su T; Zhou Q; Gao L; He Z; Wang X; Zhao J; Xing Y; Sun F; Cai W; Wang X; Han J; Qin R; Désaubry L; Han B; Chen W J Exp Clin Cancer Res; 2023 May; 42(1):128. PubMed ID: 37210546 [TBL] [Abstract][Full Text] [Related]
19. Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide. Hong Z; Xiang Z; Zhang P; Wu Q; Xu C; Wang X; Shi G; Hong Z; Wu D Clin Transl Med; 2021 Jul; 11(7):e495. PubMed ID: 34323404 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials. Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]